© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
July 14, 2021
The quality-adjusted life-year (QALY) is a popular tool for value assessment but is flawed. This paper highlights potential solutions.
November 13, 2019
Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making.
June 15, 2016
Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.
May 03, 2016
Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver failure.